1 / 54

Neuromuscular disorders in children; making sense of the muscle, lung and brain

Neuromuscular disorders in children; making sense of the muscle, lung and brain. Sleep Course-Bristol Anirban Majumdar Consultant Paediatric Neurologist. Neuromuscular conditions. Overview Diagnosis Pathophysiology Surveillance and Treatments for NMD Trends and Survival in NM disorders

moriah
Download Presentation

Neuromuscular disorders in children; making sense of the muscle, lung and brain

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Neuromuscular disorders in children; making sense of the muscle, lung and brain Sleep Course-Bristol Anirban Majumdar Consultant Paediatric Neurologist

  2. Neuromuscular conditions • Overview • Diagnosis • Pathophysiology • Surveillance and Treatments for NMD • Trends and Survival in NM disorders • Who goes into respiratory failure ? • The future • What we can do now • What we will try to do in the future • Clinical vignettes • Neuromuscular / respiratory- the interface

  3. Brain Brain stem Spinal cord Anterior horn cell Nerve Neuromuscular junction Muscle

  4. Multisystem disorders Ataxias Metabolic/ Mitochondrial Chanelopathies/ storage disorders SMA Demylinating/ Axonal Neuropathy Myesthenias Dystrophy Myopathy

  5. Tone Hypotonia is a common diagnostic problem Hypotonia = floppiness

  6. Weakness MRC evaluation of muscle power 0 – no contraction 1- flicker 2- Active movement with gravity eliminated 3- Active movement against gravity 4 - Active movement against gravity and resistance 5- Normal power + and – denotes through what range of normal movement

  7. Recognizable patterns • Hypotonia + weakness = neuromuscular disease • Hypotonia without weakness may be • CNS • birth asphyxia • CNS malformations • Metabolic • lipidoses/MPS • amino-organic acidurias • peroxisomal • Connective tissue • Ehlers-Danlos/Marfan • OI • Chromosomal • PWS • Downs

  8. Neuromuscular disorders • Presents with • floppiness • weakness • delayed motor milestones, • abnormal gait, clumsiness, • speech and swallowing difficulties • Respiratory, cardiac failure • Age : from newborn to adult life • Very wide range of severity and disability • Intelligence : very wide range

  9. History Clinical examination Genetic analysis Biochemistry Immunology Muscle imaging EMG/NCV Muscle Biopsy Nerve biopsy Immunohistochemistry

  10. Historical Notes 1851: Edward Merynon describes 10 cases in England 1861: Duchenne de Boulogne fils. De la paralysie atrophique graisseuse de l’enfance. Archives Generales de Medicine 1861 Autographed copy of: De la Paralysie Musculaire Pseudo-hypertrophique1868

  11. Clinical presentation • Delayed walking • Waddling gait • Gower sign • Pelvic muscle weakness and lumbar lordosis • Global developmental delay • Pseudo hypertrophy of muscles • Learning difficulties • Raised CK levels

  12. Duchenne (Xp21) MD • The most common muscle disorder in childhood • X-linked, 30 per 100 000 liveborn males (neonatal screening) • Symptoms appear in first 5 years

  13. Genetics • X linked with recessive inheritance • 1/3 spontaneous mutations • Affects 1 in 3500 live male births • Absence or deficiency of dystrophin in muscle membrane, smooth muscle and brain

  14. Normal DystrophiN Dystrophin Gene dystrophin pre-mRNA dystrophin mRNA DystrophiN protein

  15. Duchenne MD DysX DysXrophin Gene dysxrophin pre-mRNA dysxrophin mRNA DysX protein

  16. Becker MD DysrophiN Dys-rophin Gene dys-rophin pre-mRNA dys-rophin mRNA DysrophiN protein

  17. Surveillance and Treatments in DMD • Heart • Respiratory • Scoliosis • Maintaining ambulation

  18. Respiratory - Problems • Respiratory problems are predictable • Correlation with overall muscle strength and ambulation – rarely problems in ambulant boys • Progressive fall in FVC predicts respiratory failure • Nocturnal hypercapnia – subtle symptoms ie headaches, tiredness, poor performance at school, restless sleep

  19. Respiratory -Problems • Increased amount of chest infections • FVC <40 % indicates sleep studies • Consider flu and pneumococcal vaccination • Early antibiotic treatment • Physio: Postural drainage / assisted cough

  20. What are the symptoms of progressive respiratory failure ? • Subtle • weight loss • reduction in energy levels • poor performance at school. • Sleep disturbance • increased requirement for turning overnight. • Chest infections • frequent and difficult to treat. • Established hypercapnia and not treated • Headaches • general malaise, poor eating • high risk of death from respiratory failure during intercurrent infection.

  21. Evolution of respiratory failure in NMD Surveillance Normal breathing FVC 100% pred Monitor FVC < 60% pred REM related sleep disordered breathing Chest physio FVC < 40% pred NIV Chest infection Cough assist NREM and REM sleep disordered breathing FVC < 20% pred Daytime ventilatory failure Simonds A.

  22. Respiratory Surveillance: • Forced Vital Capacity (FVC) • absolute values and % predicted for height or arm span • easy way to document the progression of respiratory muscle weakness. • FVC drops to 1.25 l or <40% predicted value • serial measurement of overnight oxymetry and CO2 • allows the recognition of the development of nocturnal respiratory failure.

  23. Respiratory- Non-invasive ventilation • Early discussion • Indication: FVC <40 %, nocturnal hypoventilation • Mean age 17 years (Newcastle) • Improvement of daytime symptoms • Less infections • Daytime ventilation later • ? Tolerance

  24. Ventilation- the benefits • Patients notice • frequency of chest infections falls • infections that do occur may be effectively managed with the ventilator to assist coughing. • may develop a need to use the ventilator for increasing periods during the day • a portable ventilator may need to be provided that can be transported on the wheelchair. • Nocturnal ventilation • Long-term follow up studies - very effective as a treatment for respiratory failure • often nocturnal use alone provides very good stabilisation for many years. • Ventilation • mean age of death (Newcastle) 19 years to at least 25 years • survival into the fourth decade is now possible !

  25. Current Respiratory guidelines • ATS Consensus Statement: Respiratory Care of the patient with Duchenne Muscular Dystrophy AJRCCM;2004:456-65 • Recommendation for Respiratory care of children with Spinal Muscular Atrophy Type II & III Neuromusc Disord 2003;13:184-89 • Ventilatory support in Congenital Neuromuscular Disorders – congenital myopathies, congenital muscular dystrophies and SMA II Neuromusc Disord 2004;14:56-69 • MDC Recommendations for the Respiratory care of adults with Muscle Disorders (2005-in preparation) • Consensus Conference: Clin indications for NIV in CRF. Chest 1999;116: 521-4

  26. Are we getting it right ?Incidence and mortality rate for DMD (Denmark) Jeppesen J et al Neuromusc Dis 2003; 13:804-2

  27. Management trends in DMD Jeppesen J Neuromusc Dis 2003;13:804-12

  28. When to initiate NIV in NMD • Background: • NIV can be lifesaving in hypercapnic patients. • Mean survival 9.7 months in hypercapnic DMD patients if ventilatory support not provided (Vianello et al, 1997). • Survival extended in other cohorts (Bach, Eagle, Simonds). • Clinical course in other NMD not so predictable • BUT

  29. Prophylactic NIPPV in DMD Preventative / prophylactic NIV in asymptomatic normocapnic DMD patients is not beneficial Raphael et al Lancet 1994 Control NIV

  30. When to initiate NIV • Initiation of NIV at time of nocturnal hypoventilation before development of daytime hypercapnia will prevent ventilatory decompensation and improve QOL • Initiation of NIV in asymptomatic patients before the onset of sleep disordered breathing or daytime hypercapnia is NOT recommended

  31. How do we compare to others ? European use of ventilation by disease categoriesLloyd Owen ERJ 2005

  32. Cardiovascular

  33. Cardiac- Surveillance • ECG and ECHO at diagnosis, 2-yearly until 10, yearly thereafter (European Neuromuscular Centre, Netherland) • 10% of female carriers develop overt cardiac failure: ECG and ECHO at diagnosis and 5-yearly

  34. Cardiac -Treatment • Single study suggests ACE inhibitor use before cardiac abnormalities are detectable as protective in the long term • Currently treatment with ACE inhibitors +/- β-blockers is initiated when echo findings of LV dysfunction • Diuretics etc as required for complications

  35. Special case of Emery Dreyfus Muscular Dystrophy • X linked EDMD- arrythmias- pacemaker • AD EDMD- VF-implantable defibrillator

  36. Scoliosis surveillance

  37. Factors causing loss of ambulation in Duchenne • weakness • contractures progressive scoliosis rapid growth spurt falls/injury /fractures • fear • motivation Marion Main

  38. Ways of maintaining ambulation in NM disorders • maintain power • Steroids in DMD • Beta agonists in SMA • control contractures/deformity • prevent injury • Orthoses • maintain motivation • child and parents/carers Marion Main

  39. Trends in survival in DMD- secular trends Eagle et al Neuromusc Dis 2002

  40. SS= scoliosis surgery Eagle et al Neuromusc Dis 2002

  41. Joint neuro respiratory clinics- doing the right thing ? YES When is the right time to refer to the respiratory team ? EARLY

  42. Advantages of Joint Clinics • Don’t send patient to …x, y, z • Invite …x, y, z, to be part of your team

  43. Who is involved with the care of NM patients? • GP, • community paediatrician at district general hospital • hospital paediatrician at district general hospital, • paediatric neurologist at tertiary hospital, • neuromuscular specialist national centre, • paediatric respiratory consultant and nurse • paediatric cariologist • physiotherapist, • occupational therapist, • speech and language therapist, • dietician, • social worker, • geneticist, • orthotist, • wheelchair services, • orthopaedic surgeon, • spinal surgeon, • neurophysiologist, • Histopathologist, • anaesthetist, • intensivist, • special educational needs teacher. • Neuromuscular nurse specialist • palliative care team • Transitional care team to take over care on reaching adulthood MULTIDISCIPLINARY Parents

  44. The future • What we can do . • What we are trying to do.

  45. What we can do : Role of steroids • Prednisolone / Deflazacort • Regimes: • Prednisolone 0.75 mg/kg/day • Deflazacort 0.9 mg/kg/day • consider alternate day dose or steroid breaks • How long to give it? • Increase in muscle strength • Prolonged ambulation for up to 2 years • ? Improvement in cardiac function • ? Lessen scoliosis • ? Improves respiratory function Cochrane 2004: Improvement in muscle strength and function for 6 months to 2 years

More Related